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Genetic landscape of 6089 
inherited retinal dystrophies 
affected cases in Spain and their 
therapeutic and extended 
epidemiological implications
Irene Perea‑Romero1,2,59, Gema Gordo1,59, Ionut F. Iancu1,2,59, Marta Del Pozo‑Valero1,2, 
Berta Almoguera1,2, Fiona Blanco‑Kelly1,2, Ester Carreño3, Belen Jimenez‑Rolando3, 
Rosario Lopez‑Rodriguez1, Isabel Lorda‑Sanchez1,2, Inmaculada Martin‑Merida1,2, 
Lucia Pérez de Ayala1, Rosa Riveiro‑Alvarez1,2, Elvira Rodriguez‑Pinilla1, 
Saoud Tahsin‑Swafiri1,2, Maria J. Trujillo‑Tiebas1,2, The ESRETNET Study Group*, The 
ERDC Study Group*, The Associated Clinical Study Group*, Blanca Garcia‑Sandoval2,3, 
Pablo Minguez1,2, Almudena Avila‑Fernandez1,2, Marta Corton1,2,59* & Carmen Ayuso1,2,59*
Inherited retinal diseases (IRDs), defined by dysfunction or progressive loss of photoreceptors, 
are disorders characterized by elevated heterogeneity, both at the clinical and genetic levels. Our 
main goal was to address the genetic landscape of IRD in the largest cohort of Spanish patients 
reported to date. A retrospective hospital‑based cross‑sectional study was carried out on 6089 IRD 
affected individuals (from 4403 unrelated families), referred for genetic testing from all the Spanish 
autonomous communities. Clinical, demographic and familiar data were collected from each patient, 
including family pedigree, age of appearance of visual symptoms, presence of any systemic findings 
and geographical origin. Genetic studies were performed to the 3951 families with available DNA 
using different molecular techniques. Overall, 53.2% (2100/3951) of the studied families were 
genetically characterized, and 1549 different likely causative variants in 142 genes were identified. The 
most common phenotype encountered is retinitis pigmentosa (RP) (55.6% of families, 2447/4403). 
The most recurrently mutated genes were PRPH2, ABCA4 and RS1 in autosomal dominant (AD), 
autosomal recessive (AR) and X‑linked (XL) NON‑RP cases, respectively; RHO, USH2A and RPGR in 
AD, AR and XL for non‑syndromic RP; and USH2A and MYO7A in syndromic IRD. Pathogenic variants 
c.3386G > T (p.Arg1129Leu) in ABCA4 and c.2276G > T (p.Cys759Phe) in USH2A were the most frequent 
variants identified. Our study provides the general landscape for IRD in Spain, reporting the largest 
cohort ever presented. Our results have important implications for genetic diagnosis, counselling and 
new therapeutic strategies to both the Spanish population and other related populations.
Inherited retinal diseases (IRDs) are one of the most heterogeneous clinical and genetical disorders known among 
all human medical conditions, characterized by the progressive loss of photoreceptor cells, resulting in severe 
visual  impairment1. IRDs are classified as rare diseases, and their estimated prevalence is about 1 in  10002–40001. 
IRDs can be classified according to different clinical or genetic criteria, based upon the primary retinal cell 
affected (rods, cones, retinal pigment epithelium (RPE), bipolar cells or ganglion cells), the ophthalmological 
findings and/or the affected gene found after the genetic testing.
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All modes of inheritance can be observed (autosomal dominant (AD), autosomal recessive (AR), X-linked 
(XL), including rare non-Mendelian forms such as mitochondrial or digenic inheritance patterns). Age of onset of 
first symptoms (from early childhood to adulthood), rate of progression, association with extra-ocular symptoms 
(non-syndromic versus syndromic forms) or causative gene can also help to subclassify the different  phenotypes3. 
The most prevailing form of IRDs is Retinitis Pigmentosa (RP [MIM: 268000]), which is estimated to affect 
approximately 1.5 million people  worldwide4. RP begins with the degeneration of rod photoreceptors, resulting 
in night blindness and characteristic pigmentary changes in the peripheral retina. This is also considered a rod-
cone dystrophy due to the subsequent cone photoreceptor death in later stages. Other forms of IRD, including 
cone-dominated diseases, are characterized by photophobia, reduced visual acuity and impaired colour vision (i.e. 
cone dystrophy (CD), achromatopsia, blue cone monochromatism), as well as generalized retinal degeneration 
involving simultaneously both cones and rods such as in rod-cone or cone-rod dystrophies (CRD). The most 
severe form of non-syndromic IRDs is Leber congenital amaurosis (LCA) characterized by congenital or early 
childhood blindness. Other IRD forms are characterized by central vision loss affecting primarily the macula and 
are therefore acknowledged as Macular Dystrophies (MD), such as Stargardt disease (STGD1 [MIM: 248200]) 
and Best Vitelliform Macular Dystrophy (VMD2 [MIM: 153700])1.
Conversely, syndromic IRDs are subclassified according to the type of syndrome. The most prevalent is Usher 
syndrome (sensorineural hearing loss and RP) which can be further subclassified to Usher type I (USH1 [MIM: 
276900]), type II (USH2 [MIM: 276901]) and type III (USH3 [MIM: 276902]), and other syndromes such as 
Bardet-Biedl (BBS [MIM: 209900]) or Alström (ALMS [MIM: 203800])3.
Since the identification of rhodopsin (RHO [MIM: 180380]) in 1990 as the first gene involved in the develop-
ment of AD-RP5, 270 genes have been additionally described as causative of IRDs (RetNet, Retinal Information 
Network; https ://sph.uth.edu/retne t/; accessed on March 2020). Some of these genes have been reported in only 
few families worldwide; therefore, their individual contribution to IRD prevalence is relatively small. The most 
prevalent IRD-causing genes across all populations are ABCA4 (MIM: 601691), RHO, USH2A (MIM: 608400) 
and RPGR (MIM: 312610), which account for high percentages of some of the IRD subtypes, i.e. 70–71% in 
STGD1/AR-MD/AR-CRD6, 19–25% of AD-RP, 10% of AR-RP, and 70% of XL-RP,  respectively1. In addition, 
although the majority of the causative variants are private, some are more frequent, especially in Spanish families, 
such as USH2A (GenBank: NM_206933.3) c.2299delG (p.Glu767SerfsTer21) and c.2276G > T (p.Cys759Phe)7 or 
ABCA4 (GenBank: NM_000350.3) c.3386G > T (p.Arg1129Leu) and c.5882G > A (p.Gly1961Glu)6.
The aim of this study is to present a comprehensive overview of the largest cohort of IRD patients ever 
reported worldwide and related to IRD in the Spanish population. The presented data includes the presumed 
inheritance pattern for the different phenotypic subtypes, mutational spectrum, prevalence of genes carrying 
likely pathogenic variants and the recurrence of disease related variants.
Results
Prevalence of IRD in Spain. The number of cases diagnosed as having IRD in our hospital (until August 
2019) was 6089, and the last Spanish population registry accounted for 46,722,980 habitants giving us a minimal 
prevalence of 1:7673 (confidence interval (CI):1:7485–1:7871). Regional distribution of cases and prevalence can 
be seen in Fig. 1A,B. Considering a worldwide IRD prevalence of 1:10002–40001, our cohort would represent 
20–53% of the total patients with IRD in Spain as shown in Supplementary Table S1.
For non-syndromic IRD, our cohort was grouped in 2 categories: 1703 affected individuals (1335 families), in 
cone-dominated phenotypes—hereafter “NON-RP”—and 3561 affected cases from 2447 unrelated families within 
primarily rod affection—hereafter “RP”. This resulted in a minimal prevalence of 1:27,436 (CI:1:26,192–1:28,804) 
and 1:13,121 (CI:12,704–13,566) for NON-RP and RP, respectively. Additionally, syndromic IRD forms repre-
sented the smallest fraction accounting for 13.6% of the patients with 825 affected individuals (621 families), 
resulting in a minimal prevalence of 1:56,634 (CI:1:53,016–1:60,781).
In our cohort, we have a higher proportion of cases from Madrid area (26.7%; 1625/6089).
Initial classification of IRD families by clinical type and suspected mode of inheritance prior 
to genetic testing. Non-syndromic NON-RP and RP cases were categorized by the mode of inheritance 
(Fig. 2A-I and A-II). Syndromic IRD were categorized by the specific type of suspected syndrome (Fig. 2A-III), 
instead of inheritance type, given that most of them were sporadic (53.6%) or had recessive inheritance (40.2%). 
The remaining 6.2% corresponded to dominant (0.5%), X-linked (0.7%), mitochondrial inherited disease (0.2%) 
or non-classificable cases (4.8%).
According to this “a priori” diagnosis based on the clinical and familial history of the patients, the main 
inheritance pattern in non-syndromic NON-RP and RP was recessive or sporadic, representing the 68% and 
75% of cases, respectively. Autosomal dominant and X-linked forms accounted for 21% and 8% for NON-RP 
and 15% and 8% for RP, respectively (Fig. 2A-I). Families with no familiar data were annotated as unclassified. 
Non-syndromic RP represents the most common phenotype, representing 55.6% of families in our cohort.
In the present cohort, 47% of the syndromic IRD index cases (270/577) suffered from USH2, followed by 17% 
USH1 (98/577), as well as other very rare syndromes like some atypical forms of Usher syndrome (3%; 16/577) 
and ciliopathies such as BBS or ALMS (16%; 90/577). A miscellanea of non-ciliopathic syndromes or unclassified 
symptoms were presented in 103 index cases.
Molecular studies. Diagnostic yield. Genetic testing was performed in a total of 3951 index cases with 
available  DNA6–11 (89.7% of the total cohort), including 1291 NON-RP, 2083 RP, and 577 syndromic IRD pa-
tients as shown in Supplementary Fig. S1. The genetic analysis procedures evolved over time since novel ge-
netic approaches were implemented in our laboratory. A definite genetic diagnosis was established for 53.2% 
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(2100/3951) of cases. For NON-RP families, 754 out of 1291 (58.4%) obtained a genetic diagnosis; in RP the 
molecular cause was identified in 1038 out of 2083 (49.8%). Similarly, 53.4% (308/577) of syndromic IRD fami-
lies were genetically solved (Fig. 2B).
Final inheritance pattern and reclassification of characterized families. The identification of the 
causative gene allowed us to reclassify the inheritance mode in 8.2% (146/1792) of the NON-RP and RP fami-
lies, thus establishing the final inheritance type (Supplementary Table S2). A comparison between the “a priori” 
suspected inheritance based on the pedigree and the final inheritance suggested by the molecular diagnosis was 
performed in characterized NON-RP and RP families (Fig. 2C). As expected, most sporadic NON-RP (n = 378) 
and RP cases (n = 379) were confirmed as having AR inheritance after the genetic testing. The rest of the S cases 
were reclassified to AD (n = 43) and XL (n = 36) (Supplementary Table S2). Twenty-four cases (11 NON-RP and 
13 RP) with an initial unknown mode of inheritance were classified as: AD (n = 5), AR (n = 16), and XL (n = 3) 
after the molecular testing.
Gene landscape. In total, 1549 different pathogenic and likely pathogenic variants were identified in 142 differ-
ent genes. These included SNVs (Single Nucleotide Variants) and CNVs (Copy Number Variants). As showed in 
Figs. 3, 4, 5, there was a wide spectrum of genes implicated in IRD, 121 of them represented in 1% or less of the 
cohort. The 5 most frequent mutated genes were ABCA4, USH2A, RS1 (MIM: 300839), CRB1 (MIM: 604210) 
and RHO.
In NON-RP families, PRPH2 (MIM: 179605), ABCA4 and RS1 were the most commonly mutated genes, 
explaining 42.2%, 82.7% and 93.3% of the AD, AR and XL forms, respectively as shown in Supplementary 
Table S3.
For non-syndromic RP, 207 AD-RP families were genetically characterized with heterozygous variants identi-
fied in one of 23 genes found. The most frequent mutated genes were RHO (65/207; 31.4%) and PRPF31 (MIM: 
606419) (34/207; 16.4%). In AR-RP families, the most common gene mutated was USH2A (127/666; 19.1%). 
However, the number of other disease genes detected was very high (N = 70) in the 666 families characterized. 
For XL-RP families, both the number of cases and variety of genes were low (N = 9) as shown in Supplementary 
Table S4. For these patients, 41.2% (68/165) of the index cases (all males) carried a hemizygous pathogenic variant 
in RPGR (44 RPGR_ORF15 and 24 in the rest of RPGR regions), and 32.7% (54/165) in CHM (MIM: 300390).
A total of 53 cases out of the total 2100 (2.5%) were clinically reconsidered and reclassified after genetic test-
ing: 12 NON-RP were reclassified as RP (9/754; 1.2%; characterized with RHO, FSCN2, PRPF8, AHI1, CNGB1, 
TRPM1 and CHM) or as syndromic IRD (3/754; 0.4%; COL11A1, CDH3 and MYO7A) and 37 RP as NON-
RP (32/1038; 3.1%; C1QTNF5, GUCA1A, CNGB3, CNGA3, ACBD5, GNAT2, PDE6C, ATF6, PDE6H, RS1 and 
OPN1LW-OPN1MW), syndromic IRD (1/1038; 0.1%; MYO7A) and other visual diseases, such as exudative 
Figure 1.  IRD affected cases distribution and estimated prevalence in Spain. (A) Distribution of RP/NON-RP 
affected cases across Spain. Total cases: 6089 (known Spanish origin: 4668; unknown origin: 1421). Spanish map 
modified using image editor from https ://www.veoma pas.com/mapa-mudo-de-las-comun idade s-auton omas-
de-espan a-m103.html. (B) IRD estimated prevalence in Spanish regions. Data was obtained from the number of 
cases we had in our Hospital Service and the recorded population in the different regions. *Inconclusive data.
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Figure 2.  “A priori” and final classification of IRD affected cases. (A) “A priori” classification of IRD families 
with data obtained from the clinical and family history of the patients, before performing molecular tests: 
NON-RP (I), RP (II), and syndromic IRD (III), and subclassification according to the inheritance type in case of 
RP and NON-RP, and type of syndrome in case of syndromic IRD. Data obtained with the clinical and familiar 
history of the patients, before performing molecular tests. AD Autosomal Dominant, AR autosomal recessive, 
S sporadic, XL X-linked. (B) Proportion of genetically solved NON-RP, RP, syndromic IRD and total IRD. 
The diagnostic ratio in the different group of NON-RP and RP by the type of “a priori” inheritance and in the 
different group of syndromic IRD by type of syndrome is indicated. (C) Genetically solved families. Comparison 
of inheritance classification before (light gray) and after (dark gray) the molecular study was performed.
Figure 3.  Classification of mutated genes in the genetically solved NON-RP affected cases. Below each gene is 
given the percentage that each gene was mutated in the cohort. Total characterized families: AD-NON-RP: 121; 
AR-NON-RP: 544; XL-NON-RP: 89.
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familiar vitreoretinopathy, optic atrophy, albinism and gyrate atrophy (4/1038; 0.4%; FZD4, OPA1, GPR143 and 
OAT). Moreover, 4 syndromic cases were reclassified to RP group (4/308; 1.3%; RDH12, PDE6A and RPGRIP1).
Among syndromic IRD families, the causative gene was identified in 56 families with a diagnosis of USH1, 
145 of USH2, 6 of atypical Usher, and 101 of other syndromes including Bardet-Biedl or Alström syndrome, 
respectively. In USH1, biallelic variants in MYO7A (MIM: 276903) were identified in 30 out of 56 patients 
(53.5%). USH2A defects were the main cause of USH2 in 90% (129/145) of the patients. The group “others” was 
a clinically heterogeneous group of non-Usher cases with a total of 48 involved genes, with BBS1 (MIM: 209901) 
being the most frequent one (N = 23), as shown in Supplementary Table S5.
In addition to clinical and genetic heterogeneity, the group of “others” included in syndromic IRD also 
presented unusual modes of inheritance, such as triallelism. In our cohort, 4 possible triallelic cases have been 
identified, all of them diagnosed with BBS, 3 patients carrying biallelic BBS1 variants together with one allele in 
MKKS (MIM: 604896)9,12 and one additional case carrying biallelic MKKS variants and one allele in BBS5 (MIM: 
Figure 4.  Classification of mutated genes in the genetically solved RP affected cases. Below each gene is given 
the percentage that each gene was mutated in the cohort. Total characterized families: AD-RP: 207; AR-RP: 666; 
XL-RP: 165.
Figure 5.  Classification of mutated genes in the genetically solved syndromic IRD affected cases. Below each 
gene is given the percentage that each gene was mutated in the cohort. Total characterized families: Usher I: 56; 
Usher II: 145; Others (including atypical Usher): 107.
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603650). The phenotypic modifier effect of the triallelism could only be stablished in two of the 4 families. One 
has two affected siblings with different phenotypic severity that correlates with the presence of the third allele; 
and in the other both affected showed triallelism and have the same clinical manifestation. Although, it could 
not be stablished in the rest of the families, as they were sporadic cases.
Most frequent variants. Our findings reflect the high allelic heterogeneity in IRD. We identified 458 different 
disease-causing variants in 45 genes in cases “a priori” classified as NON-RP, as well as 836 in 94 genes in the 
“a priori” RP cases and 295 in 55 genes in the “a priori” syndromic IRD. The most common pathogenic variant 
detected in our NON-RP cohort was the previously known missense change ABCA4 c.3386G > T (p.Arg1129Leu) 
(180 mutated alleles of 3,618; 5% of the total pathogenic alleles), presented in 21.5% (162/754) of the character-
ized families, in homozygous or compound heterozygous state in 18 and 144 families, respectively (Supplemen-
tary Table S6). Among the RP families, the most prevalent pathogenic variant was the missense change USH2A 
c.2276G > T (p.Cys759Phe), identified in 106 alleles in 8.4% of the solved families (87/1038); in 19 cases in 
homozygous and in 68 cases in compound heterozygous state. In addition, there were 15 other variants present 
in more than 10 genes (Supplementary Table S6). Some of the mutated genes overlap in NON-RP (Fig. 3), RP 
(Fig. 4) and syndromic IRD (Fig. 5).
Disease-causing variant distribution in Spain. Analysis of causing variants by the different Spanish regions 
resulted in a wide variety of disease-causing variants. Table 1 shows variants detected in more than 5% of char-
acterized families, by Spanish regions. All these variants are depicted in the Supplementary Table S6 of NON-RP 
and RP most frequent causing variants, except for the nonsense variant PRCD (OMIM: 610598) (GenBank: 
NM_001077620.3) c.64C > T (p.Arg22Ter), that was found in homozygosity in 3 families, representing 7.2% 
(6/83) of the identified alleles from Murcia.
Discussion
This is the first and largest comprehensive study addressing the prevalence and epidemiology of IRD in the Span-
ish population. The cohort here described, comprising 6089 cases from 4403 unrelated families, is not based on 
a national registry of IRD patients, but it is the outcome of a very wide recruiting effort of a single center over 
the last 28 years. An increasing number of centers are currently performing clinical and/or genetic diagnosis of 
IRD in Spain, therefore our cohort did not reflect all of IRD patients in our country. Hence, to date, no accurate 
data about the IRD prevalence in the Spanish population is available.
In terms of representation of patients from the different Spanish regions, our cohort reflects a biased recruit-
ment, being enriched with patients from Madrid and the surrounding regions (i.e. Castile and Leon, Castile-La 
Mancha, and Extremadura) probably due to the fact that our hospital has been their referral center during 
most of the time of the study. Other areas like Andalusia, Catalonia, Navarre or the Valencian Community had 
different referral centers and genetic testing is performed locally. In spite of these limitations, the large sample 
size of our cohort and the exhaustive molecular analysis performed over the years, together with an overall low 
genetic heterogeneity in the Spanish  population13, have allowed a straightforward extrapolation of prevalent 
genes and/or variants in IRD. Considering a worldwide prevalence of 1:10002–40001 and an estimated Spanish 
population of 46.7 million, our cohort would represent 20–53% of the total patients with IRD in Spain. Despite 
numerous studies about the characteristics of the different IRDs in Spain, such as NON-RP and RP have been 
partially published, still no global overview of NON-RP and RP diseases using a representative cohort has been 
addressed yet before in our country.
Table 1.  Variants detected in > 5% of NON-RP, RP and syndromic IRD by Spanish regions. Regions with 
variants detected below this percentage are not represented in the table, and neither are regions with less than 
50 mutated alleles in total or variants that were presented less than 5 times. In bold the variant which not 
appeared as one of the most frequent variants in Supplementary Table S6.
Spanish region Gene Nucleotide change Amino acid change Nº of alleles
Nº of total alleles of this 
gene found in the region Frequency in the region
NON-RP
Basque Country
ABCA4 c.3386G > T p.Arg1129Leu 18
93
19.40%
ABCA4 c.5882G > A p.Gly1961Glu 5 5.40%
Castile-La Mancha ABCA4 c.3386G > T p.Arg1129Leu 8 60 13.30%
Madrid ABCA4 c.3386G > T p.Arg1129Leu 47 373 12.60%
Murcia
ABCA4 c.3386G > T p.Arg1129Leu 8
71
11.30%
ABCA4 c.5882G > A p.Gly1961Glu 7 9.90%
Non-syndromic RP and 
syndromic IRD
Murcia
USH2A c.2276G > T p.Cys759Phe 11
83
13.30%
PRCD c.64C > T p.Arg22Ter 6 7.20%
Canary Islands NR2E3 c.932G > A p.Arg311Gln 8 83 9.60%
Castile-La Mancha USH2A c.2276G > T p.Cys759Phe 18 202 8.90%
Madrid USH2A c.2276G > T p.Cys759Phe 50 714 7.00%
Extremadura USH2A c.2276G > T p.Cys759Phe 5 87 5.70%
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Several studies on IRD have been performed globally (Supplementary Table S7) and, in the two last years, 
some including big  cohorts14–16 or meta-analysis17 have been published, reporting more than 125 genes explaining 
55–62% of the families using several molecular techniques to achieve  that14–16 as it could be also seen in this study.
Other studies focused on stablishing the prevalence of IRD in certain regions has been performed in Western 
countries and in cohorts of non-syndromic RP, including Western Australia (1:6000)18 or Maine (1:4756)19, as 
well as in cohorts with general IRD and an estimated prevalence of 1:3454 in  Denmark20 or 1:3856 in  Norway21. 
However, this prevalence has been reported in areas and populations with low rates of consanguinity and could 
be higher when consanguinity rate  increases2, which is not the common scenario in Spain nowadays.
Our study identified AR inheritance as the most common mode of inheritance for non-syndromic IRD, 
explaining up to 70–75% NON-RP and RP subcohorts (Fig. 2A-I and A-II). By contrast, only 7% of our NON-
RP and RP families are explained by X-linked genes. These results were consistent with previous studies 
 published18–22. Besides, some cases could be explained by different molecular mechanisms as the pseudodomi-
nance, incomplete penetrance or the presence of two variants in an AR gene in AD a priori  families8, so extended 
segregation analysis within these families are needed. Additional non-Mendelian transmission patterns were 
only found in exceptionally rare cases with syndromic IRD, including 3 families carrying variants affecting the 
mitochondrial DNA and 4 cases with apparent triallelism in BBS-associated genes. Within syndromic IRD group, 
most of the cases were explained by AR biallelic monogenic inheritance. Similar to previous published studies 
from other  countries3,23, Usher syndrome was the most prevalent form of syndromic IRD in our cohort, and 
more specifically, USH2, representing almost half of the total syndromic IRD families.
The overall diagnostic rate of 53.2% obtained here is similar to other studies previously reported (50–70%)24–26. 
Molecular studies allowed the identification of the genes responsible for the disease and the reclassification of 
the inheritance type. In our work, 8.2% of the patients were reclassified after the detection of the disease-causing 
variants in genes with a specific inheritance pattern. All of those were or have been previously validated. Moreo-
ver, in all the characterized sporadic cases a more accurate genetic classification and counselling could be  done8. 
Additionally, a 2.5% were clinically reclassified after the genetic testing, due to a poor clinical data acquisition 
at the origin center. So, identification of the genetic cause of the disease represents a hallmark for the patients, 
firstly, regarding genetic counselling and the risk of affectation for other relatives; and secondly, given the pos-
sibility of future recruitments for clinical trials targeting specific genes and variants.
A total of 142 different genes were identified as the cause of IRD in our study, but it is important to notice 
that each subgroup of the cohort (AD, AR and XL NON-RP and RP) has an enrichment of characterized cases 
in specific genes.
For instance, PRPH2 was mutated in more than a third of AD-NON-RP families, followed by BEST1 (MIM: 
607854). As expected, ABCA4 was the most prevalent gene in AR-NON-RP families. Recent studies in  Norway21 
and  Korea22 also identified this gene as one of the most prevalent mutated genes. A study published by Birtel 
et al.27 in patients with MD and cone/cone-rod dystrophy showed a similar distribution of mutated genes, with 
ABCA4, PRPH2 and BEST1 responsible for 74% of their solved cases. For the XL-NON-RP subcohort, RS1 was 
the most frequently mutated gene.
Non-syndromic RP presented a wider spectrum of causative genes, with RHO, USH2A and RPGR (RPGR_
ORF15 and the rest of RPGR regions) being the most prevalent ones in AD-RP, AR-RP and XL-RP subcohorts, 
respectively. Our findings are in line with those published in other  studies8,28. For instance, Hartong et al.3, 
showed as well MYO7A, USH2A and BBS1 to be the most frequently mutated genes in USH1, USH2 and BBS, 
respectively. Other studies in different populations highlighted different genes as the most representative in their 
IRD cohorts. For example, Eisenberger et al.24 described RP1 (MIM: 603937) (11.3%) and EYS (MIM: 612424) 
(9.4%) as the most frequent genes in German patients with AR-RP, and Kim et al.22 detected that EYS (22%) 
and PDE6B (MIM: 180072) (17%) are most frequently involved in AR-RP in Korean patients. EYS was also the 
most prevalent causative gene in the Japanese population studied by Maeda et al.29, implicated in 21 out of 33 
AR-RP patients (63.6%), whereas in our population EYS was mutated in 5.5% of the families with “a priori” 
AR-RP diagnosis, being the fourth most frequent gene, after USH2A, CRB1 and ABCA4. However, the order 
of the causative genes in AR-RP changes after reviewing the clinical data of ABCA4 related IRD patients, since 
they were mostly reclassified as NON-RP, downgrading EYS as the third most common gene in AR-RP in our 
population. This result supports an eastward gradient in the frequency of EYS variants in patients throughout 
the world and within Europe, being more frequent in Germany than in Spain.
The most frequent causing variants detected in our study appeared, as expected, in ABCA4 and USH2A, the 
most prevalent mutated genes in the Spanish  population6–8,30. ABCA4 c.3386G > T (p.Arg1129Leu) is a variant 
almost exclusively found in Spanish NON-RP  patients6,30, being probably a Spanish founder  mutation31,32. How-
ever, USH2A c.2276G > T (p.Cys759Phe) is not exclusive from the Spanish population and has been reported 
in other  populations33.
According to the geographical distribution of the variants within the country, no differences between regions 
were observed. In NON-RP, the two most common ABCA4 variants were also the most represented in regions 
with variant frequencies above 5%. Meanwhile, in RP we found a higher representation of the most common 
USH2A variant, which appeared above 5% of the total alleles in four regions. Finally, two variants appeared 
to be more frequent in some regions, i.e. PRCD c.64C > T (p.Arg22Ter) in Murcia and NR2E3 (MIM: 604485) 
(GenBank: NM_014249.4) c.932G > A (p.Arg311Gln) in the Canary Islands, where a founder effect could be 
happening.
Our results delineate the genetic background of the Spanish IRD patients, indicating a wide range of causative 
genes involved in the disease. Some of the causing variants identified are also frequent in Europe. Some examples 
include the ABCA4 c.5882G > A (p.Gly1961Glu), reported with high prevalence in the Italian, German and Span-
ish  populations30,34,35; the c.2276G > T (p.Cys759Phe) as one of the most frequent variants in USH2A, especially 
in European  countries36, USH2A c.2299delG (p.Glu767SerfsTer21), which is possibly an ancestral European 
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pathogenic  variant37; BBS1 (GenBank: NM_024649.5) c.1169T > G (p.Met390Arg), identified previously by 
Mykytyn et al.38 in 22 North American BBS probands with North European ancestry; and CRB1 (GenBank: 
NM_201253.3) c.2843G > A (p.Cys948Tyr), identified repeatedly in different European  countries39,40. Finally, 
RHO (GenBank: NM_000539.3) c.1040C > T (p.Pro347Leu), described in the Italian and French  populations41,42 
and also in non-European  cohorts5,43,44.
Variants found in individuals from East Mediterranean and Middle-Eastern countries also appeared in 
our Spanish cohort: PRCD c.64C > T (p.Arg22Ter) found by Sharon et al.14 in homozygosis in 15 Israeli Mus-
lim Arab families, and by Beheshtian et al.45 in a Persian family; and FAM161A (MIM: 613596) (GenBank: 
NM_001201543.2) c.1355_1356delCA (p.Thr452SerfsTer3), which was identified in Jewish families mainly 
originating from North African  countries46. As mentioned above, the variant in PRCD was found with a higher 
frequency in the region of Murcia, and this could be due to the settlement of Muslim populations during several 
centuries during the Middle  Ages13. FAM161A does not have a significant specific geographical distribution in 
Spain.
Remarkably, we identified three pathogenic variants with high frequency in Spain: ABCA4 c.3386G > T 
(p.Arg1129Leu), previously mentioned; CERKL (MIM: 608381) (GenBank: NM_201548.5) c.847C > T 
(p.Leu283Phe), first described by Tuson et al.47, and RP1 c.1625C > G (p.Ser542Ter) previously described origi-
nally as a Spanish founder pathogenic variant. These three variants had been scarcely reported outside the Span-
ish population. In the case of RP1 c.1625C > G (p.Ser542Ter)  variant48, because of its presence in 11 out of 244 
unrelated families, we can extrapolate that it may very well account for approximately 4.5% of all AR-RP cases 
in the Spanish population. Other groups also identified this variant in Swiss  patients26.
In conclusion, this study shows the general landscape of the genetic underpinnings of IRD in Spain and will 
help design clinical and preventive healthcare approaches to this disorder in our country.
Materials and methods
Cohort description. A retrospective analysis was performed including all IRD patients from our Spanish 
registry at the Fundación Jiménez Díaz University Hospital (FJD, Madrid, Spain) from 1991 until August 2019. 
This patient registry includes: all patients referred to the Genetic Service at the FJD for genetic diagnostic testing 
and/or counselling due to a previous clinical suspicion of IRD, and patients without genetic analysis in our unit 
but identified in the shared electronic clinical history of our same-company hospitals using ICD (International 
Classification of Diseases) terms. The complete cohort contains 6089 IRD affected cases (including index cases 
and affected relatives) belonging to 4403 unrelated families as shown in Supplementary Fig. S1.
This study was approved by the Ethics Committee of the FJD under approval number 134/2016_FJD and 
fulfilled all the tenets of the Declaration of Helsinki and its further reviews. A written informed consent form 
was obtained from all the patients or their legal guardians.
IRD classification and diagnostic criteria. During this study, different clinical, demographic and famil-
iar data were collected, including (i) family pedigree; (ii) age at onset of visual acuity loss, extent of visual field 
loss, night blindness and/or other early symptoms of retinal dystrophy; (iii) presence of any systemic findings 
suggestive of syndromic forms of IRD; (iv) geographical origin of the patients.
Clinical diagnosis was based on ophthalmic examination, including measurement of best-corrected visual 
acuity, visual field testing, fundus examination and, if possible, full-field electroretinography, fundus autofluores-
cence and spectral domain optical coherence tomography scan. NON-RP and RP include non-syndromic IRD, 
and their clinical classification was done according to previously described  criteria6,8. NON-RP group include 
most patients with CD, CRD and achromatopsia, although some of them were included in the RP group due to 
incomplete phenotyping at the moment of the diagnosis. Non-syndromic LCA cases were also included in RP.
For NON-RP and RP families, an “a priori” inheritance pattern (AD/AR/XL/sporadic (S)) was established 
according to previously described  criteria1. The subgroup of XL-RP also included choroideremia cases.
For cases not extensively described in the first referral, a generic classification was made as NON-RP or RP.
Criteria for syndromic IRD diagnosis were previously  described7,9.
Information about the geographic origin of all the IRD cases from Spain was available in 4668. They are 
distributed throughout the 17 different Spanish communities (Fig. 1A).
Inheritance reclassification of IRD cases. After molecular diagnosis, inherited patterns were reviewed 
and compared with “a priori” data of each family. Statistical analysis between these data sets to assess the global 
association in the NON-RP group was made using the Fisher’s exact test with a p equal to 0.497. Whereas for the 
RP group, Chi-square test was used with a p below 0.001. Comparisons for each type of inheritance have also 
been made with the Fisher’s exact test in the NON-RP Unclassified subgroup and with the Chi-square test in 
the rest. Fisher’s exact test was used in those cases in which more than 20% of expected values were below than 
5, or at least one of the expected frequencies was below 1. Regarding the significance levels chosen, we have a 
global comparison for which the significance level is the usual threshold of 0.05 and p-value is not corrected, and 
several post-hoc comparisons for which Bonferroni’s multiple comparisons adjustment is applied, multiplying 
the p-values by the number of comparisons.
Prevalence of IRD. In this study, we performed a retrospective analysis of the largest cohort of patients with 
IRD from Spain, whom were recruited during a period of 28 years by a single center, the FJD. The FJD is a center 
of reference for molecular diagnosis of IRD from all over the country, especially in some specific autonomous 
communities, like Castile and Leon, Castile-La Mancha, Extremadura or Madrid. On the other hand, as we 
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take into account other Spanish regions, there are other centers of reference and the prevalence data obtained is 
inconclusive.
Prevalence was calculated for each clinical type of the disease by dividing the total number of diagnosed 
IRD cases by the total population in Spain, published by the Spanish Statistical Office (INE; http://www.ine.es) 
in January 2019.
Genomic screening. Genomic DNA samples were obtained from the FJD Biobank from a total of 3951 
families (89.7%), including 1291 NON-RP, 2083 non-syndromic RP and 577 syndromic IRD families. Molecular 
studies were performed using different molecular techniques as shown in Supplementary Table S8. According 
to the technology available and the knowledge on the genetic determinants of IRD at the time of the diagnosis, 
a maximum of 291 different genes involved in IRD were processed for the molecular characterization (Supple-
mentary S1 Appendix). In these studies, index cases were initially screened, analysed following the American 
College of Medical Genetics and Genomics (ACMG; https ://www.acmg.net/docs/stand ards_guide lines _for_
the_inter preta tion_of_seque nce_varia nts.pdf) variants classification guidelines. If potentially disease-causing 
variants were found, segregation analysis was performed when DNA samples from relatives were available.
In the general description of mutated genes and frequent pathogenic variants, only fully molecularly char-
acterized index cases were considered. Patients with a heterozygote allele in a recessive gene were counted as 
uncharacterized.
The frequency of recurrent IRD causing variants was established considering not only the total Spanish 
population, but also the different geographical regions of Spain (Fig. 1A), in order to assess the possibility of 
identifying any endemic or founder effects. Pathogenic variants with a prevalence above 5% in a particular region 
were recorded, and only those with a higher prevalence were considered for further analysis.
Data availability
Part of the NGS data are available in public, open access repositories such as the European Genome-Phenome 
Archive (EGA; https ://www.ebi.ac.uk/ega/home; EGAD00001005746 and EGAD00001005498), RD-Connect 
(https ://rd-conne ct.eu/) and the Collaborative Spanish Variant Server (CSVS; http://csvs.babel omics .org/) as 
aggregated data. The rest of the data are available upon reasonable request.
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